AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection ...
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline ...
JLL Partners (“JLL” or the “Firm”), a New York-based middle market private equity firm focused on investing in the healthcare ...
The global hospital information systems (HIS) market is projected to register a compound annual growth rate (CAGR) of ...
Round led by Heran Partners and joined by Clave Capital, Inveready and Bio&Tech Smart CapitalFinancing will enable ...
The global beauty supplements market is projected to expand at a compound annual growth rate (CAGR) of 7% during the forecast ...
GOTHENBURG, SE / ACCESS Newswire / February 18, 2026 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A)(STO:IRLAB-A)(FRA:6IRA ...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, ...
ANK-203 is a first-in-class anchored immunotherapy designed to unlock the full therapeutic potential of monoclonal antibody CD137 through localized delivery and retentionIn preclinical studies, ...
Lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s diseaseKRSA-028 preclinical data support potential for a best-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results